Martinson E A, Scheible S, Greinacher A, Presek P
Rudolf-Buchheim-Institut für Pharmakologie, Justus-Liebig-Universität Giessen, Federal Republic of Germany.
Biochem J. 1995 Sep 1;310 ( Pt 2)(Pt 2):623-8. doi: 10.1042/bj3100623.
Blood platelets contain phospholipase D (PLD) that is rapidly activated following platelet stimulation. It is currently unclear, however, where PLD fits into the signalling cascade that leads to aggregation and secretion. Therefore we investigated the mechanism of activation of PLD in human platelets, using the formation of the PLD-specific product phosphatidylethanol as a measure of PLD activity. PLD was activated by a number of platelet agonists that also cause the activation of protein kinase C, including thrombin, collagen, the Ca2+ ionophore A23187 and the thromboxane A2-mimetic U46619. Phorbol 12-myristate 13-acetate (PMA), a direct activator of protein kinase C, also increased PLD activity. A selective inhibitor of protein kinase C, Ro-31-8220, totally blocked the stimulation of PLD by thrombin or PMA under conditions in which it also inhibited phosphorylation of pleckstrin, the major protein kinase C substrate in platelets. Ro-31-8220 additionally inhibited A23187-stimulated PLD activity, indicating that Ca2+ activation of PLD also occurs via a protein kinase C-dependent pathway. In the presence of the fibrinogen antagonist peptide RGDS, which inhibits fibrinogen binding to integrin alpha IIb beta 3 and allows little or no aggregation to occur, thrombin- and PMA-stimulated PLD activity was still observed, indicating that PLD activation is not simply a consequence of platelet aggregation. Furthermore, these agonists were able to stimulate PLD in platelets from a Glanzmann's thrombasthenia type I patient lacking the integrin alpha IIb beta 3 complex, which indicates that activation of PLD is also independent of the recruitment of integrin alpha IIb beta 3. Taken together, our results show that PLD is activated by a pathway involving protein kinase C, and suggest that PLD might be involved in signal transduction events occurring upstream of integrin alpha IIb beta 3 activation and fibrinogen binding, which are prerequisites for full platelet aggregation.
血小板含有磷脂酶D(PLD),在血小板受到刺激后会迅速被激活。然而,目前尚不清楚PLD在导致聚集和分泌的信号级联反应中处于何种位置。因此,我们利用PLD特异性产物磷脂酰乙醇的形成作为PLD活性的指标,研究了人血小板中PLD的激活机制。PLD可被多种也能激活蛋白激酶C的血小板激动剂激活,包括凝血酶、胶原蛋白、Ca2+离子载体A23187和血栓素A2模拟物U46619。蛋白激酶C的直接激活剂佛波酯12 -肉豆蔻酸酯13 -乙酸酯(PMA)也能增加PLD活性。蛋白激酶C的选择性抑制剂Ro - 31 - 8220在抑制血小板中主要蛋白激酶C底物血小板-白细胞C激酶底物蛋白(pleckstrin)磷酸化的条件下,完全阻断了凝血酶或PMA对PLD的刺激。Ro - 31 - 8220还抑制了A23187刺激的PLD活性,表明Ca2+对PLD的激活也通过蛋白激酶C依赖性途径发生。在存在抑制纤维蛋白原与整合素αIIbβ3结合且几乎不发生或不发生聚集的纤维蛋白原拮抗剂肽RGDS的情况下,仍观察到凝血酶和PMA刺激的PLD活性,这表明PLD激活不仅仅是血小板聚集的结果。此外,这些激动剂能够刺激来自一名缺乏整合素αIIbβ3复合物的I型Glanzmann血小板无力症患者的血小板中的PLD,这表明PLD的激活也独立于整合素αIIbβ3的募集。综上所述,我们的结果表明PLD通过涉及蛋白激酶C的途径被激活,并提示PLD可能参与整合素αIIbβ3激活和纤维蛋白原结合上游发生的信号转导事件,而这些事件是血小板完全聚集的先决条件。